Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.
Investigational PrEP Injection, Dosed Every Other Month, Holds Up Against Daily PrEP in Phase 3 Study
The long-acting injectable drug cabotegravir proved non-inferior to daily oral TDF/FTC for MSM and transgender women.
Some advocates support it but want to ensure protections against criminalization.
May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.
Our Newest Posts
Recent studies examine the role anal sex is playing in HIV rates and anal cancer among women.
May 28, 2020: Anal lesion recurrence among women with HIV; non-alcoholic fatty liver disease frequency in lean patients; long-term efficacy for a smoking cessation intervention; non-lymphoid cancers following lymphoid malignancy.
This researcher has some ideas about what we need to do to address the problem.
Natalia Linos, Sc.D., M.Sc., of Harvard University’s FXB Center for Health and Human Rights, calls for protections for low-wage essential workers and releasing people from jails, prisons, and ICE detention.
Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.
Home HIV and STI testing is now being endorsed by the Centers for Disease Control and Prevention to start or continue pre-exposure prophylaxis (PrEP).